HIGH INCIDENCE OF ADVANCED STAGE PROSTATE CANCER IN RIAU PROVINCE OF INDONESIA
Keywords:
Prostate cancer, Prostate Spesific Antigen, Digital Rectal Examination, Bone scan, Androgen, Deprivative TherapyAbstract
Introduction: Indonesia is in the fifth position of the most prostate cancer incidence countries in Asia with the rate of 10.6 per 100.000 cases from all group of age and the mortality rate is about 8 per 100.000 cases. The objective of this study is to identify the characteristics of advanced stage prostate cancer patients.
Materials and Methods: We reviewed the medical records of 42 advanced stage prostate cancer men of all 103 prostate cancer men in Arifin Achmad Regional General Hospital Pekanbaru Riau Province, Indonesia, from January 2010 to December 2016.
Results: There were 103 adenocarcinoma of prostate patients from January 2010 to December 2016 consisting of 61 (59.2%) initial staging and 42 (40.8%) advanced stage prostate cancer patients in which included in this study. Most (40.5%) advanced stage prostate cancer patients were 61-70 years old. Most (88.1%) abnormal finding were found in digital rectal examination (DRE). Most (28.6%) patients had 61-80 ml prostate volume with Transrectal Ultrasound (TRUS). Most (47.6%) patients had initial Prostate Specific Antigen (PSA) >100 ng/ml with Gleason Score were mostly (81%) poorly differentiated. The bone scan results showed that 30 patients (71.4%) were positive for metastasis. The treatment with Androgen Deprivation Therapy (ADT) show the highest modality (78.6%).
Conclusions: We found high incidence of advanced prostate cancers with high ages, high abnormality in DRE, high prostate volumes with TRUS, high PSA levels, high poorly differentiated adenocarsinomas, high Gleason Scores, high metastasis in bone scans and high treatment with ADTs.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Author/s retain the copyright of their article, with first publication rights granted to Medsci Publications.